Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
Earnings Data
Report Date
Aug 18, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-7.97Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial momentum: very high revenue growth, substantial margin expansion, multiple quarters of positive adjusted EBITDA and free cash flow, a large and growing genomic data asset, and encouraging interim MCED (Caris Detect) results (AUC 0.90, Stage I/II sensitivity 63.1%). Management outlined committed reinvestment in commercial expansion, R&D and MCED capacity while maintaining positive cash flow. Key risks and near-term uncertainties include the interim nature of MCED data (blinded validation and ACHIEVE-2 pending), reimbursement and ASP variability, a meaningful increase in OpEx and CapEx for 2026, and uneven pharma revenue cadence. On balance, the positive financial performance, strong cash position and promising product pipeline outweigh the listed risks.Company Guidance
Record Quarterly and Annual Revenue Growth
Q4 total revenue of $293M, up 125% year-over-year; full-year total revenue growth ~97% year-over-year. Molecular profiling revenues reached $282M in Q4 (up 199% YoY) and $766.7M for the full year (up 120% YoY).
Strong Profitability and Cash Generation
Q4 GAAP net income of $82M, Q4 adjusted EBITDA of $106M and positive free cash flow of $39.7M. Full-year adjusted EBITDA of $138M and full-year free cash flow of $67M. Cash on hand grew to slightly above $800M (increase of $43M in the quarter).
Improved Margins
Q4 GAAP gross margin improved to 75% (vs. 54% in Q4 2024 and 68% in Q3 2025). Full-year GAAP molecular profiling gross margin finished at ~66% (64% excluding additional prior‑year collections).
Volume and ASP Expansion
Clinical profiling volumes ~199,300 cases in 2025 (volume growth ~22% year-over-year for the year; 20% quarter-over-quarter growth in Q4). Clinical ASP increases: company reported a 150% clinical ASP increase (CEO commentary); full-year tissue ASP for 2025 cases ~$3,876 and blood ASP just above $2,500. Tissue ASP increased ~83% to >$4,000 and blood ASP increased ~69% to just under $2,800 (full-year trends).
Platform Scale and Data Assets
Platform milestone: more than 1 million profiled cases and ~50+ billion molecular markers; dataset includes ~627,000 exomes, ~678,000 transcriptomes and ~740,000 match profiles — strengthening product development and biopharma partnerships.
Promising ACHIEVE-1 (Caris Detect) Interim Results
ACHIEVE-1 interim (2,122 samples: 617 cancer, 1,505 controls) showed Stage I sensitivity 56.8% (n=266), Stage II 70.1% (n=137), Stage III 77% (n=105), Stage IV 99.1% (n=109); combined Stage I+II sensitivity 63.1%. Specificity: 99.1% in the screening cohort (n=121 with follow-up) and 95.3% in the higher-risk normal cohort (1,505). Overall AUC 0.90. A blinded holdout (~865 samples) is in process; ACHIEVE-2 enrollment and processing underway.
Commercial Momentum and Coverage
MI Cancer Seek represented >70% of tissue volume for the year and >75% in Q4; program covers >225 million lives. Therapy selection volumes up ~20% for the quarter and ~22% for the year. Caris Assure delivered 59% YoY growth in Q4.
2026 Financial Guidance with Growth and Investment
2026 guidance: total revenue for existing solutions of $1.00B–$1.02B (approx. 23%–26% growth). Clinical therapy selection volume expected to grow ~20%. Molecular profiling growth ~21%–22% (26%–28% excluding prior-year accruals). Tissue ASP target ~ $4,000 in Q1 and ~$4,200 for FY2026; blood ASP guidance $2,400–$2,500. Pharma & research revenue guidance $75M–$85M. Company expects to remain positive on adjusted EBITDA and free cash flow while investing.
Strategic Investment Plan
Planned reinvestment in commercial expansion (salesforce +20%–25% from ~250 to ~300 reps), R&D and pipeline (including ACHIEVE-2 and MRD development), and capacity build for early detection with FY2026 CapEx guidance of ~$60M (up from ~$16M in 2025).
CAI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CAI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $19.24 | $20.14 | +4.68% |
Nov 05, 2025 | $29.21 | $24.61 | -15.75% |
Aug 12, 2025 | $32.46 | $34.28 | +5.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Caris Life Sciences, Inc. (CAI) report earnings?
Caris Life Sciences, Inc. (CAI) is schdueled to report earning on Aug 18, 2026, After Close (Confirmed).
What is Caris Life Sciences, Inc. (CAI) earnings time?
Caris Life Sciences, Inc. (CAI) earnings time is at Aug 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CAI EPS forecast?
Currently, no data Available